Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
6 "T790M"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Lung and Thoracic cancer
Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer
Jang Ho Lee, Eun Young Kim, Cheol-Kyu Park, Shin Yup Lee, Min ki Lee, Seong-Hoon Yoon, Jeong Eun Lee, Sang Hoon Lee, Seung Joon Kim, Sung Yong Lee, Jun Hyeok Lim, Tae-Won Jang, Seung Hun Jang, Kye Young Lee, Seung Hyeun Lee, Sei Hoon Yang, Dong Won Park, Chan Kwon Park, Hye Seon Kang, Chang Dong Yeo, Chang-Min Choi, Jae Cheol Lee
Cancer Res Treat. 2023;55(1):112-122.   Published online July 19, 2022
DOI: https://doi.org/10.4143/crt.2022.381
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Although osimertinib is the standard-of-care treatment of epidermal growth factor receptor (EGFR) T790M mutation–positive non–small cell lung cancer, real-world evidence on the efficacy of osimertinib is not enough to reflect the complexity of the entire course of treatment. Herein, we report on the use of osimertinib in patients with EGFR T790M mutation–positive non–small cell lung cancer who had previously received EGFR tyrosine kinase inhibitor (TKI) treatment in Korea.
Materials and Methods
Patients with confirmed EGFR T790M after disease progression of prior EGFR-TKI were enrolled and administered osimertinib 80 mg daily. The primary effectiveness outcome was progression-free survival, with time-to-treatment discontinuation, treatment and adverse effects leading to treatment discontinuation, and overall survival being the secondary endpoints.
Results
A total of 558 individuals were enrolled, and 55.2% had investigator-assessed responses. The median progression-free survival was 14.2 months (95% confidence interval [CI], 13.0 to 16.4), and the median time-to-treatment discontinuation was 15.0 months (95% CI, 14.1 to 15.9). The median overall survival was 36.7 months (95% CI, 30.9 to not reached). The benefit with osimertinib was consistent regardless of the age, sex, smoking history, and primary EGFR mutation subtype. However, hepatic metastases at the time of diagnosis, the presence of plasma EGFR T790M, and the shorter duration of prior EGFR-TKI treatment were poor predictors of osimertinib treatment. Ten patients (1.8%), including three with pneumonitis, had to discontinue osimertinib due to severe adverse effects.
Conclusion
Osimertinib demonstrated its clinical effectiveness and survival benefit for EGFR T790M mutation–positive in Korean patients with no new safety signals.

Citations

Citations to this article as recorded by  
  • The importance of re-biopsy in the era of molecular therapy for lung cancer
    Nensi Lalic, Daliborka Bursac, Marko Bojovic, Marko Nemet, Ivan Ergelasev
    Srpski arhiv za celokupno lekarstvo.2024; 152(3-4): 209.     CrossRef
  • Detection of EGFR exon 20 insertion mutations in non-small cell lung cancer: implications for consistent nomenclature in precision medicine
    Jieun Park, Boram Lee, Ji-Young Song, Minjung Sung, Mi Jeong Kwon, Chae Rin Kim, Sangjin Lee, Young Kee Shin, Yoon-La Choi
    Pathology.2024; 56(5): 653.     CrossRef
  • Real‐world study of lazertinib as second‐line or greater treatment in advanced non‐small cell lung cancer
    Jeong Uk Lim, Kyuhwan Kim, Kyu Yean Kim, Hye Seon Kang, Ah. Young Shin, Chang Dong Yeo, Sung Kyoung Kim, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim
    Thoracic Cancer.2024; 15(19): 1513.     CrossRef
  • Comparative effectiveness of lazertinib in patients with EGFR T790M-positive non-small-cell lung cancer using a real-world external control
    Ha-Lim Jeon, Meesong Kwak, Sohee Kim, Hye-Yeon Yu, Ju-Young Shin, Hyun Ae Jung
    Scientific Reports.2024;[Epub]     CrossRef
  • A Randomized, Multi-Center, Open Label Study to Compare the Safety and Efficacy between Afatinib Monotherapy and Combination Therapy with HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR Mutations
    Eunbin Kwag, Soo-Dam Kim, Seong-Hoon Shin, Chulho Oak, So-Jung Park, Jun-Yong Choi, Seong Hoon Yoon, In-Cheol Kang, Mi-Kyung Jeong, Hyun Woo Lee, Sun-Hwi Bang, Ji Woong Son, Sanghun Lee, Seung Joon Kim, Hwa-Seung Yoo
    Integrative Cancer Therapies.2024;[Epub]     CrossRef
  • Clinical utility of repeated rebiopsy for EGFR T790M mutation detection in non-small cell lung cancer
    Eun Hye Lee, Se Hyun Kwak, Kyeong Yeon Kim, Chi Young Kim, Sang Hoon Lee, Seok-Jae Heo, Yoon Soo Chang, Eun Young Kim
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study
    Qing Zhou, He-Long Zhang, Li-Yan Jiang, Yuan-Kai Shi, Yuan Chen, Jin-Ming Yu, Cai-Cun Zhou, Yong He, Yan-Ping Hu, Zong-An Liang, Yue-Yin Pan, Wen-Lei Zhuo, Yong Song, Gang Wu, Gong-Yan Chen, You Lu, Cui-Ying Zhang, Yi-Ping Zhang, Ying Cheng, Shun Lu, Chan
    Journal of Cancer Research and Clinical Oncology.2023; 149(12): 10771.     CrossRef
  • 6,809 View
  • 324 Download
  • 9 Web of Science
  • 7 Crossref
Close layer
Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion
Yeon Joo Kim, Won Jun Ji, Jae-Cheol Lee, Sung-Min Chun, Chang-Min Choi
Cancer Res Treat. 2022;54(4):985-995.   Published online January 17, 2022
DOI: https://doi.org/10.4143/crt.2021.857
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study was to evaluate anti-tumor efficacy of osimertinib in patients positive for acquired epidermal growth factor receptor (EGFR) T790M mutation in liquid biopsy using plasma, bronchoalveolar lavage fluid (BALF) or bronchial washing fluid (BWF), and pleural effusion.
Materials and Methods
Among patients benefited from previous EGFR‒tyrosine kinase inhibitor treatment followed by treatment failure, patients in whom T790M mutations are detected in at least one of the samples including tumor tissues, BALF/BWF, plasma, and pleural effusion were enrolled. T790M mutation was detected by extracting cell free DNA from liquid biopsy samples, using PANA Mutyper. Objective response rate (ORR) and progression-free survival (PFS) with osimertinib treatment were evaluated.
Results
Between January 2018 and December 2019, 63 patients were enrolled and received osimertinib. Mean age was 63 years, and 38 (60.3%) were female. Twenty-six patients had T790M mutation in both liquid and tissue samples (group A), 19 patients had only in tissue biopsy samples (group B), and 18 patients had T790M mutation only in liquid biopsy samples (group C). ORR in overall population was 63.5%, and was 61.5% in group A, 68.4% in group B, and 61.1% in group C, respectively. Median PFS in overall patients was 15.6 months (95% confidence interval, 10.7 to 24.2). There was no significant difference in ORR or PFS between groups.
Conclusion
Osimertinib showed favorable efficacy in lung cancer patients with acquired resistance to prior EGFR-TKI therapies, who screened positive for harboring T790M mutation detected from cell free DNA extracted from plasma, BALF/BWF, and pleural effusion.

Citations

Citations to this article as recorded by  
  • Repeated rebiopsy for detection of EGFR T790M mutation in patients with advanced-stage lung adenocarcinoma: Associated factors and treatment outcomes of Osimertinib
    Taeyun Kim, Junsu Choe, Sun Hye Shin, Byeong-Ho Jeong, Kyungjong Lee, Hojoong Kim, Se-Hoon Lee, Sang-Won Um, Hamidreza Montazeri Aliabadi
    PLOS ONE.2024; 19(9): e0310079.     CrossRef
  • Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
    Yi-Ze Li, Sheng-Nan Kong, Yun-Peng Liu, Yue Yang, Hong-Mei Zhang
    Journal of Clinical Medicine.2023; 12(4): 1438.     CrossRef
  • Usefulness of bronchial washing fluid for detection of EGFR mutations in non-small cell lung cancer
    Woo Kyung Ryu, Seung Hyun Yong, Sang Hoon Lee, Hye Ran Gwon, Hye Ryun Kim, Min Hee Hong, Go Eun Oh, Sehee Jung, Chi Young Kim, Yoon Soo Chang, Eun Young Kim
    Lung Cancer.2023; 186: 107390.     CrossRef
  • 5,885 View
  • 226 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer
Chaelin Lee, Miso Kim, Dong-Wan Kim, Tae Min Kim, Soyeon Kim, Sun-Wha Im, Yoon Kyung Jeon, Bhumsuk Keam, Ja-Lok Ku, Dae Seog Heo
Cancer Res Treat. 2022;54(1):140-149.   Published online May 3, 2021
DOI: https://doi.org/10.4143/crt.2021.385
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Epidermal growth factor receptor kinase domain duplication (EGFR-KDD) is a rare and poorly understood oncogenic mutation in non–small cell lung cancer (NSCLC). We aimed to investigate the acquired resistance mechanism of EGFR-KDD against EGFR-TKIs.
Materials and Methods
We identified EGFR-KDD in tumor tissue obtained from a patient with stage IV lung adenocarcinoma and established the patient-derived cell line SNU-4784. We also established several EGFR-KDD Ba/F3 cell lines: EGFR-KDD wild type (EGFR-KDDWT), EGFR-KDD domain 1 T790M (EGFR-KDDD1T), EGFR-KDD domain 2 T790M (EGFR-KDDD2T), and EGFR-KDD both domain T790M (EGFR-KDDBDT). We treated the cells with EGFR tyrosine kinase inhibitors (TKIs) and performed cell viability assays, immunoblot assays, and ENU (N-ethyl-N-nitrosourea) mutagenesis screening.
Results
In cell viability assays, SNU-4784 cells and EGFR-KDDWT Ba/F3 cells were sensitive to 2nd generation and 3rd generation EGFR TKIs. In contrast, the T790M-positive EGFR-KDD Ba/F3 cell lines (EGFR-KDDT790M) were only sensitive to 3rd generation EGFR TKIs. In ENU mutagenesis screening, we identified the C797S mutation in kinase domain 2 of EGFR-KDDBDT Ba/F3 cells. Based on this finding, we established an EGFR-KDD domain 1 T790M/domain 2 cis-T790M+C797S (EGFR-KDDT/T+C) Ba/F3 model, which was resistant to EGFR TKIs and anti-EGFR monoclonal antibody combined with EGFR TKIs.
Conclusion
Our study reveals that the T790M mutation in EGFR-KDD confers resistance to 1st and 2nd generation EGFR TKIs, but is sensitive to 3rd generation EGFR TKIs. In addition, we identified that the C797S mutation in kinase domain 2 of EGFR-KDDT790M mediates a resistance mechanism against 3rd generation EGFR TKIs.

Citations

Citations to this article as recorded by  
  • A Constitutive EGFR Kinase Dimer to Study Inhibitor Pharmacology
    Justin J. Kim, Ilse K. Schaeffner, David E. Heppner, Ciric To, Pasi A. Jänne, Tyler S. Beyett, Michael J. Eck
    Molecular Pharmacology.2024; 105(2): 97.     CrossRef
  • Tumor-associated Macrophages Mediate Gefitinib Resistance in Lung Cancer through HGF/c-met Signaling Pathway
    Xiali Tang, Yu Chen, Demin Jiao, Xiang Liu, Jun Chen, Yongyang Liu, Chunyan Jiang, Qingyong Chen
    Anti-Cancer Agents in Medicinal Chemistry.2024; 24(1): 30.     CrossRef
  • Colorectal cancer harboring EGFR kinase domain duplication response to EGFR tyrosine kinase inhibitors
    Tomohiro Kondo, Osamu Kikuchi, Yoshihiro Yamamoto, Tomohiko Sunami, Yafeng Wang, Keita Fukuyama, Tomoki Saito, Hideto Nakahara, Sachiko Minamiguchi, Masashi Kanai, Atsushi Sueyoshi, Manabu Muto
    The Oncologist.2024;[Epub]     CrossRef
  • Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer
    Ziyang Jiang, Zhihan Gu, Xiaomin Yu, Tao Cheng, Bofu Liu
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Molecular Targets and Mechanisms of Casein-Derived Tripeptides Ile-Pro-Pro and Val-Pro-Pro on Hepatic Glucose Metabolism
    Chenyang Wang, Lin Zheng, Mouming Zhao
    Journal of Agricultural and Food Chemistry.2023; 71(48): 18802.     CrossRef
  • Erlotinib

    Reactions Weekly.2022; 1907(1): 208.     CrossRef
  • 9,026 View
  • 335 Download
  • 5 Web of Science
  • 6 Crossref
Close layer
A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, In-Jae Oh, Young-Chul Kim
Cancer Res Treat. 2019;51(2):777-787.   Published online September 7, 2018
DOI: https://doi.org/10.4143/crt.2018.387
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Administering the best treatment after failure of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy requires knowledge of resistance status. In this trial, treatment efficacy of osimertinib was assessed in patients with non-small cell lung carcinoma (NSCLC) harboring the T790M resistance mutation, detected from circulating tumor DNA (ctDNA) with unknown tumor mutation status.
Materials and Methods
To extract ctDNA from plasma, 15 mL of peripheral blood was withdrawn and centrifuged immediately before storage. Cobas ver. 2 and PANA Mutyper were used for ctDNA genotyping. Patients with T790M, detected from ctDNA, were enrolled and they received a oncedaily administration of osimertinib 80 mg. The primary endpoint was objective response rate (ORR), and secondary endpoints were ctDNA test sensitivity, progression-free survival (PFS), duration of response (DoR), and safety.
Results
Eighty patients with acquired resistance to prior EGFR-TKI therapies were screened. ctDNA of 21 patients showed T790M positivity, and 19 patients were enrolled. In the responseevaluable population (n=15), ORR was 66.7% (10/15). Median PFS was 8.3 months (95% confidence interval [CI], 7.9 to 8.7) and median DoR was 6.8 months (95% CI, 5.3 to 8.3) in the intent-to-treat population (n=19). No subject experienced drug-related adverse event of grades ≥ 3 or required dose reduction. The sensitivity of the ctDNA tests was 56.8% using both methods and 45.9% with either method from the estimated T790M-positive cases.
Conclusion
Osimertinib has favorable efficacy in patients with NSCLC harboring T790M, detected from ctDNA with unknown tumor mutation status, in whom disease had progressed during prior EGFR-TKI therapy.

Citations

Citations to this article as recorded by  
  • CDC6 may serve as an indicator of lung adenocarcinoma prognosis and progression based on TCGA and GEO data mining and experimental analyses
    Hao Lou, Zelai Wu, Guangyou Wei
    Oncology Reports.2024;[Epub]     CrossRef
  • Liquid biopsy for the management of NSCLC patients under osimertinib treatment
    Aliki Ntzifa, Theodoros Marras, Vasilis Georgoulias, Evi Lianidou
    Critical Reviews in Clinical Laboratory Sciences.2024; 61(5): 347.     CrossRef
  • The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non‐small cell lung cancer: A meta‐analysis
    Liuxian Guo, Guojin Zhou, Min Huang, Kejing Tang, Jing Xu, Jie Chen
    The Clinical Respiratory Journal.2024;[Epub]     CrossRef
  • A novel prognostic signature based on smoking-associated genes for predicting prognosis and immune microenvironment in NSCLC smokers
    Qixuan Li, Tianyi Wang, Yijie Tang, Xian Zou, Zhongqi Shen, Zixin Tang, Youlang Zhou, Jiahai Shi
    Cancer Cell International.2024;[Epub]     CrossRef
  • Deciphering Dormant Cells of Lung Adenocarcinoma: Prognostic Insights from O-glycosylation-Related Tumor Dormancy Genes Using Machine Learning
    Chenfei Dong, Yang Liu, Suli Chong, Jiayue Zeng, Ziming Bian, Xiaoming Chen, Sairong Fan
    International Journal of Molecular Sciences.2024; 25(17): 9502.     CrossRef
  • Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
    Yi-Ze Li, Sheng-Nan Kong, Yun-Peng Liu, Yue Yang, Hong-Mei Zhang
    Journal of Clinical Medicine.2023; 12(4): 1438.     CrossRef
  • Cuproptosis-related signature predicts prognosis, immunotherapy efficacy, and chemotherapy sensitivity in lung adenocarcinoma
    Gujie Wu, Qin Hu, Hongyu Chen, Min He, Huiyun Ma, Lin Zhou, Kun Xu, Hefei Ren, Juntao Qi
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • The Utility of ctDNA in Lung Cancer Clinical Research and Practice: A Systematic Review and Meta-Analysis of Clinical Studies
    Xuezheng Sun, Page Abrahamson, Nicholas Ballew, Linda Kalilani, Kelesitse Phiri, Kelly F. Bell, Alexander Slowley, Magdalena Zajac, Erin Hofstatter, Alexander Stojadinovic, Angela Silvestro, Zebin Wang, Amine Aziez, Solange Peters
    Cancer Investigation.2023; 41(6): 571.     CrossRef
  • Clinical application of liquid biopsy based on circulating tumor DNA in non-small cell lung cancer
    Liu Xin, Yang Yue, Ren Zihan, Cui Youbin, Lu Tianyu, Wang Rui
    Frontiers in Physiology.2023;[Epub]     CrossRef
  • Usefulness of bronchial washing fluid for detection of EGFR mutations in non-small cell lung cancer
    Woo Kyung Ryu, Seung Hyun Yong, Sang Hoon Lee, Hye Ran Gwon, Hye Ryun Kim, Min Hee Hong, Go Eun Oh, Sehee Jung, Chi Young Kim, Yoon Soo Chang, Eun Young Kim
    Lung Cancer.2023; 186: 107390.     CrossRef
  • Current treatment of non-small cells lung cancer with EGFR mutation: first-line and management upon progression
    Sergio Sandiego Contreras, Lucía Morales López, Reyes Claramunt Alonso, Javier Lavernia Giner, Ignacio Gil Bazo
    Revisiones en Cáncer.2023;[Epub]     CrossRef
  • A novel neutrophil extracellular traps-related lncRNA signature predicts prognosis in patients with early-stage lung adenocarcinoma
    Huan Wang, Yueli Shi, Xia Xu, Shumin Xu, Yuting Shi, Weiyu Chen, Kai Wang
    Annals of Medicine.2023;[Epub]     CrossRef
  • Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non-Small-Cell Lung Cancer
    Jiaqi Zhu, Yun Jiang, Tianyi Wang, Anqi Wu, Tingting Zhou, Anping Zhang, Yijie Tang, Zihao Shen, Jinjie Wang, Hao Zhou, Jiahai Shi, Jianle Chen, Ihtisham Bukhari
    Disease Markers.2022; 2022: 1.     CrossRef
  • The potential of liquid biopsy in the management of cancer patients
    A. Markou, E. Tzanikou, E. Lianidou
    Seminars in Cancer Biology.2022; 84: 69.     CrossRef
  • Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
    Miguel García-Pardo, Maisam Makarem, Janice J. N. Li, Deirdre Kelly, Natasha B. Leighl
    British Journal of Cancer.2022; 127(4): 592.     CrossRef
  • Targeting Glioblastoma Stem Cells to Overcome Chemoresistance: An Overview of Current Therapeutic Strategies
    Hyunkoo Kang, Haksoo Lee, Dahye Kim, Byeongsoo Kim, JiHoon Kang, Hae Yu Kim, HyeSook Youn, BuHyun Youn
    Biomedicines.2022; 10(6): 1308.     CrossRef
  • Identification of molecular subtypes, risk signature, and immune landscape mediated by necroptosis-related genes in non-small cell lung cancer
    Jiaqi Zhu, Jinjie Wang, Tianyi Wang, Hao Zhou, Mingming Xu, Jiliang Zha, Chen Feng, Zihao Shen, Yun Jiang, Jianle Chen
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Sotorasib and other drugs comparison in treating non-small cell lung cancer
    Yueting Ren
    Highlights in Science, Engineering and Technology.2022; 8: 675.     CrossRef
  • Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion
    Yeon Joo Kim, Won Jun Ji, Jae-Cheol Lee, Sung-Min Chun, Chang-Min Choi
    Cancer Research and Treatment.2022; 54(4): 985.     CrossRef
  • Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer
    Xiaoxu Fang, Shaokun Yu, Yingying Jiang, Yan Xiang, Kaihua Lu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Phase II open‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid‐Lung‐A
    Cheol‐Kyu Park, Sung‐Yong Lee, Jae Cheol Lee, Chang‐Min Choi, Shin Yup Lee, Tae‐Won Jang, In‐Jae Oh, Young‐Chul Kim
    Thoracic Cancer.2021; 12(4): 444.     CrossRef
  • A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
    Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, In-Jae Oh, Young-Chul Kim
    Cancer Research and Treatment.2021; 53(1): 93.     CrossRef
  • Gene signatures of 6-methyladenine regulators in women with lung adenocarcinoma and development of a risk scoring system: a retrospective study using the cancer genome atlas database
    Chundi Gao, Jing Zhuang, Huayao Li, Cun Liu, Chao Zhou, Lijuan Liu, Fubin Feng, Changgang Sun
    Aging.2021; 13(3): 3957.     CrossRef
  • Identifying and Validating Potential Biomarkers of Early Stage Lung Adenocarcinoma Diagnosis and Prognosis
    Yingji Chen, Longyu Jin, Zhibin Jiang, Suo Liu, Wei Feng
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • PIWI‐interacting RNAs are aberrantly expressed and may serve as novel biomarkers for diagnosis of lung adenocarcinoma
    Juan Li, Nan Wang, Fang Zhang, Shan Jin, Yaqi Dong, Xiangjun Dong, Yuqing Chen, Xue Kong, Yao Tong, Qi Mi, Yinghui Zhao, Yi Zhang
    Thoracic Cancer.2021; 12(18): 2468.     CrossRef
  • Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment
    Hao Zhou, Miaosen Zheng, Muqi Shi, Jinjie Wang, Zhanghao Huang, Haijian Zhang, Youlang Zhou, Jiahai Shi
    BMC Cancer.2021;[Epub]     CrossRef
  • Molecular subtypes based on ferroptosis-related genes and tumor microenvironment infiltration characterization in lung adenocarcinoma
    Weiju Zhang, Sumei Yao, Hua Huang, Hao Zhou, Haomiao Zhou, Qishuang Wei, Tingting Bian, Hui Sun, Xiaoli Li, Jianguo Zhang, Yifei Liu
    OncoImmunology.2021;[Epub]     CrossRef
  • Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
    Bin Qiu, Wei Guo, Fan Zhang, Fang Lv, Ying Ji, Yue Peng, Xiaoxi Chen, Hua Bao, Yang Xu, Yang Shao, Fengwei Tan, Qi Xue, Shugeng Gao, Jie He
    Nature Communications.2021;[Epub]     CrossRef
  • Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs
    Zhenli Diao, Yanxi Han, Rui Zhang, Jinming Li
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2020; 1873(2): 188363.     CrossRef
  • Rescue of Non-Informative Circulating Tumor DNA to Monitor the Mutational Landscape in NSCLC
    Stefanie Mayer, Gerlinde Schmidtke-Schrezenmeier, Christian Buske, Frank G. Rücker, Thomas F.E. Barth, Peter Möller, Ralf Marienfeld
    Cancers.2020; 12(7): 1917.     CrossRef
  • Diverse fragment lengths dismiss size selection for serum cell-free DNA: a comparative study of serum and plasma samples
    Yanqin Huang, Jiayi Mu, Lina Qi, Weiting Ge, Xuefeng Fang, Yongmao Song, Ying Yuan, Shu Zheng
    Clinical Chemistry and Laboratory Medicine (CCLM).2020; 58(9): 1451.     CrossRef
  • The efficacy and safety of osimertinib in treating nonsmall cell lung cancer
    Jing Liu, Xuemei Li, Yinghong Shao, Xiyun Guo, Jinggui He
    Medicine.2020; 99(34): e21826.     CrossRef
  • Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin
    Ryan Woodhouse, Meijuan Li, Jason Hughes, David Delfosse, Joel Skoletsky, Pei Ma, Wei Meng, Ninad Dewal, Coren Milbury, Travis Clark, Amy Donahue, Dan Stover, Mark Kennedy, Jennifer Dacpano-Komansky, Christine Burns, Christine Vietz, Brian Alexander, Prit
    PLOS ONE.2020; 15(9): e0237802.     CrossRef
  • Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response
    Rui-Yu Li, Zhi-Yong Liang
    Chinese Medical Journal.2020; 133(20): 2476.     CrossRef
  • Identification of Key Genes in Lung Adenocarcinoma and Establishment of Prognostic Mode
    Zhou Jiawei, Mu Min, Xing Yingru, Zhang Xin, Li Danting, Liu Yafeng, Xie Jun, Hu Wangfa, Zhang Lijun, Wu Jing, Hu Dong
    Frontiers in Molecular Biosciences.2020;[Epub]     CrossRef
  • Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of Cancer
    Kelly C.S. Oliveira, Iago Barroso Ramos, Jessica M.C. Silva, Williams Fernandes Barra, Gregory J. Riggins, Vikrant Palande, Catarina Torres Pinho, Milana Frenkel-Morgenstern, Sidney E.B. Santos, Paulo P. Assumpcao, Rommel R. Burbano, Danielle Queiroz Calc
    Molecular Cancer Research.2020; 18(4): 517.     CrossRef
  • Monitoring circulating tumor DNA by analyzing personalized cancer-specific rearrangements to detect recurrence in gastric cancer
    Young-Woo Kim, Young-Ho Kim, Yura Song, Han-Seong Kim, Hye Won Sim, Shiv Poojan, Bang Wool Eom, Myeong-Cherl Kook, Jungnam Joo, Kyeong-Man Hong
    Experimental & Molecular Medicine.2019; 51(8): 1.     CrossRef
  • Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer
    Lei Huang, Hao Huang, Xiao-Ping Zhou, Jin-Feng Liu, Chun-Rong Li, Min Fang, Jun-Rong Wu
    Medicine.2019; 98(43): e17705.     CrossRef
  • 15,191 View
  • 375 Download
  • 42 Web of Science
  • 38 Crossref
Close layer
The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Kun-Chieh Chen, Chia-Hung Hsu, Kang-Yi Su, Jeremy J. W. Chen, Huei-Wen Chen, Sung-Liang Yu, Tsung-Ying Yang, Gee-Chen Chang
Cancer Res Treat. 2018;50(4):1294-1303.   Published online January 4, 2018
DOI: https://doi.org/10.4143/crt.2017.512
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The main objective of this study was to investigate the relationship among the clinical characteristics and the frequency of T790M mutation in advanced epidermal growth factor receptor (EGFR)‒mutant lung adenocarcinoma patients with acquired resistance after firstline EGFR‒tyrosine kinase inhibitor (TKI) treatment.
Materials and Methods
We enrolled EGFR-mutant stage IIIB-IV lung adenocarcinoma patients, who had progressed to prior EGFR-TKI therapy, and evaluated their rebiopsy EGFR mutation status.
Results
A total of 205 patients were enrolled for analysis. The overall T790M mutation rate of rebiopsy was 46.3%. The T790M mutation rates among patients with exon 19 deletion mutation, exon 21 L858R point mutation, and other mutations were 55.0%, 37.3%, and 27.3%, respectively. Baseline exon 19 deletion was associated with a significantly higher frequency of T790M mutation (adjusted odds ratio, 2.14; 95% confidence interval [CI], 1.20 to 3.83; p=0.010). In the exon 19 deletion subgroup, there was a greater prevalence of T790M mutation than other exon 19 deletion subtypes in patients with the Del E746-A750 mutation (61.6% vs. 40.6%; odds ratio, 2.35; 95% CI, 1.01 to 5.49; p=0.049). The progression-free survival (PFS) of first-line TKI treatment > 11 months was also associated with a higher T790M mutation rate (54.1% vs. 39.3%; adjusted odds ratio, 1.82; 95% CI, 1.02 to 3.25; p=0.044). Patients who underwent rebiopsy at metastatic sites had more chance to harbor T790M mutation (52.6% vs. 33.8%; adjusted odds ratio, 1.97; 95% CI, 1.06 to 3.67; p=0.032).
Conclusion
PFS of first-line EGFR-TKI, rebiopsy site, EGFR exon 19 deletion and its subtype Del E746- A750 mutation are associated with the frequency of T790M mutation.

Citations

Citations to this article as recorded by  
  • RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants
    Kazumi Nishino, Jin-Yuan Shih, Kazuhiko Nakagawa, Martin Reck, Edward B. Garon, Michelle Carlsen, Tomoko Matsui, Carla Visseren-Grul, Ernest Nadal
    JTO Clinical and Research Reports.2024; 5(2): 100624.     CrossRef
  • Epidermal Growth Factor Receptor Exon 19 Deletion Subtypes Do Not Influence Survival Outcomes Following First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitors in Advanced Nonsmall Cell Lung Cancer Patients
    Yan-Jei Tang, John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu
    Journal of Cancer Research and Practice.2024; 11(1): 28.     CrossRef
  • CRISPR-Based Fluorescent Reporter (CBFR) Assay for Sensitive, Specific, Inexpensive, and Visual Detection of a Specific EGFR Exon 19 Deletion in NSCLC
    Pouya Salehipour, Mojdeh Mahdiannasser, Ghazal Sedaghat Shayegan, Kimia Shankaie, Mina Tabrizi, Majid Mojarrad, Mohammad Hossein Modarressi
    Molecular Biotechnology.2023; 65(5): 807.     CrossRef
  • Endobronchial ultrasound‐guided re‐biopsy of non–small cell lung cancer with acquired resistance after EGFR tyrosine kinase inhibitor treatment
    Kyung Soo Hong, Jinmo Cho, Jong Geol Jang, Min Hye Jang, June Hong Ahn
    Thoracic Cancer.2023; 14(4): 363.     CrossRef
  • Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
    Chun-Ta Huang, Chih-An Lin, Te-Jen Su, Ching-Yao Yang, Tzu-Hsiu Tsai, Chia-Lin Hsu, Wei-Yu Liao, Kuan-Yu Chen, Chao-Chi Ho, Chong-Jen Yu
    BMC Cancer.2023;[Epub]     CrossRef
  • Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations
    Jinfei Si, Yue Hao, Jingwen Wei, Jing Xiang, Chunwei Xu, Qiuping Shen, Zhengbo Song
    BMC Pulmonary Medicine.2023;[Epub]     CrossRef
  • FRET probe for detecting two mutations in one EGFR mRNA
    Myat Thu, Kouta Yanai, Hajime Shigeto, Shohei Yamamura, Kazunori Watanabe, Takashi Ohtsuki
    The Analyst.2023; 148(11): 2626.     CrossRef
  • Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
    Michael J. Grant, Jacqueline V. Aredo, Jacqueline H. Starrett, Paul Stockhammer, Iris K. van Alderwerelt van Rosenburgh, Anna Wurtz, Andrew J. Piper-Valillo, Zofia Piotrowska, Christina Falcon, Helena A. Yu, Charu Aggarwal, Dylan Scholes, Tejas Patil, Chr
    Clinical Cancer Research.2023; 29(11): 2123.     CrossRef
  • NSCLC presents metabolic heterogeneity, and there is still some leeway for EGF stimuli in EGFR-mutated NSCLC
    Cindy Mendes, Isabel Lemos, Inês Francisco, Teresa Almodôvar, Fernando Cunha, Cristina Albuquerque, Luís G. Gonçalves, Jacinta Serpa
    Lung Cancer.2023; 182: 107283.     CrossRef
  • Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first‐line tyrosine kinase inhibitors: A single‐center ambispective cohort study
    Yangchun Gu, Jinyu Yu, Haifeng Hu, Hua Zhang, Baoshan Cao, Li Liang
    Thoracic Cancer.2023; 14(31): 3147.     CrossRef
  • Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
    Jia-Shiuan Ju, Allen Chung-Cheng Huang, Pi-Hung Tung, Chi-Hsien Huang, Tzu-Hsuan Chiu, Chin-Chou Wang, How-Wen Ko, Fu-Tsai Chung, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
    Scientific Reports.2023;[Epub]     CrossRef
  • Afatinib treatment in a large real‐world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation
    Chi‐Hsien Huang, Jia‐Shiuan Ju, Tzu‐Hsuan Chiu, Allen Chung‐Cheng Huang, Pi‐Hung Tung, Chin‐Chou Wang, Chien‐Ying Liu, Fu‐Tsai Chung, Yueh‐Fu Fang, Yi‐Ke Guo, Chih‐Hsi Scott Kuo, Cheng‐Ta Yang
    International Journal of Cancer.2022; 150(4): 626.     CrossRef
  • The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
    Yen-Hsiang Huang, Kuo-Hsuan Hsu, Chun-Shih Chin, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J.W. Chen, Gee-Chen Chang
    Cancer Research and Treatment.2022; 54(2): 434.     CrossRef
  • Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer
    Le-Tian Huang, Shu-Ling Zhang, Cheng-Bo Han, Jie-Tao Ma
    Lung Cancer.2022; 166: 9.     CrossRef
  • Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI
    John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu
    Cancers.2022; 14(4): 977.     CrossRef
  • Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer
    Minehiko Inomata, Masahiro Matsumoto, Isami Mizushima, Kana Hayashi, Zenta Seto, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Kazuyuki Tobe
    The Egyptian Journal of Bronchology.2022;[Epub]     CrossRef
  • Pretreatment Neutrophil-to-Lymphocyte Ratio and Smoking History as Prognostic Factors in Advanced Non–Small Cell Lung Cancer Patients Treated with Osimertinib
    Ji Young Park, Seung Hun Jang, Chang Youl Lee, Taehee Kim, Soo Jie Chung, Ye Jin Lee, Hwan Il Kim, Joo-Hee Kim, Sunghoon Park, Yong Il Hwang, Ki-Suck Jung
    Tuberculosis and Respiratory Diseases.2022; 85(2): 155.     CrossRef
  • Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
    Rong Liu, Jianying Zhou, Xia Ling
    Clinical Medicine Insights: Oncology.2022;[Epub]     CrossRef
  • State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan
    Yung-Hung Luo, Kung-Hao Liang, Hsu-Ching Huang, Chia-I Shen, Chi-Lu Chiang, Mong-Lien Wang, Shih-Hwa Chiou, Yuh-Min Chen
    International Journal of Molecular Sciences.2022; 23(13): 7037.     CrossRef
  • Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT)
    Urška Janžič, Nina Turnšek, Mircea Dediu, Ivan Shterev Donev, Roxana Lupu, Gabriela Teodorescu, Tudor E. Ciuleanu, Adam Pluzanski
    Current Oncology.2022; 29(8): 5833.     CrossRef
  • Efficacy and Failure Patterns of Early SBRT to the Primary Tumor in Advanced EGFR-Mutation-Positive Lung Cancer with EFGR-TKI Treatment: A Prospective, Single Arm, Phase II Study
    Yangyang Shi, Hailing Xu, William Y. Raynor, Jiapei Ding, Ling Lin, Chao Zhou, Wei Wang, Yinnan Meng, Xiaomai Wu, Xiaofeng Chen, Dongqing Lv, Haihua Yang
    Life.2022; 12(12): 1954.     CrossRef
  • Association of hOGG1‐Cys variants with occurrence of p53 and EGFR deletion mutations in non‐small cell lung cancer
    Ming‐Jenn Chen, Ching‐Ju Shen, Lee Wang, Po‐Ming Chen, Chih‐Yi Chen, Huei Lee
    Thoracic Cancer.2021; 12(4): 534.     CrossRef
  • The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
    Wen-Chien Cheng, Te-Chun Hsia, Chih-Yen Tu, Hung-Jen Chen
    OncoTargets and Therapy.2021; Volume 13: 13425.     CrossRef
  • EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis
    Jeng-Shiuan Tsai, Po-Lan Su, Szu-Chun Yang, Chao-Chun Chang, Chia-Ying Lin, Yi-Ting Yen, Yau-Lin Tseng, Wu-Wei Lai, Chien-Chung Lin, Wu-Chou Su
    Journal of the Formosan Medical Association.2021; 120(9): 1729.     CrossRef
  • The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
    Yen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Tsung-Ying Yang, Gee-Chen Chang
    Scientific Reports.2021;[Epub]     CrossRef
  • First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer
    Allen Chung-Cheng Huang, Chi-Hsien Huang, Jia-Shiuan Ju, Tzu-Hsuan Chiu, Pi-Hung Tung, Chin-Chou Wang, Chien-Ying Liu, Fu-Tsai Chung, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
    Therapeutic Advances in Medical Oncology.2021;[Epub]     CrossRef
  • Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
    Po-Yen Chen, Chin-Chou Wang, Chien-Ning Hsu, Chung-Yu Chen
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancer
    Xinying Li, Cen Chen, Zimu Wang, Jiaxin Liu, Wei Sun, Kaikai Shen, Yanling Lv, Suhua Zhu, Ping Zhan, Tangfeng Lv, Yong Song
    Cancer Cell International.2021;[Epub]     CrossRef
  • Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience
    Paola Ulivi, Elisabetta Petracci, Matteo Canale, Ilaria Priano, Laura Capelli, Daniele Calistri, Elisa Chiadini, Paola Cravero, Alice Rossi, Angelo Delmonte, Lucio Crinò, Giuseppe Bronte
    Biomedicines.2021; 9(10): 1299.     CrossRef
  • Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non–small cell lung cancer patients
    Po-Hsin Lee, Kun-Chieh Chen, Kuo-Hsuan Hsu, Yen-Hsiang Huang, Jeng-Sen Tseng, Tsung-Ying Yang, Gee-Chen Chang
    Anti-Cancer Drugs.2021; 32(10): 1099.     CrossRef
  • Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy
    Alessandro Dal Maso, Martina Lorenzi, Elisa Roca, Sara Pilotto, Marianna Macerelli, Valentina Polo, Fabiana Letizia Cecere, Alessandro Del Conte, Giorgia Nardo, Vanessa Buoro, Daniela Scattolin, Sara Monteverdi, Loredana Urso, Elisabetta Zulato, Stefano F
    Clinical Lung Cancer.2020; 21(1): 1.     CrossRef
  • Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
    Ching-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, Kuan-Yu Chen, Tzu-Hsiu Tsai, Chia-Lin Hsu, Kang-Yi Su, Yih-Leong Chang, Chen-Tu Wu, Chia-Chi Hsu, Bin-Chi Liao, Wei-Hsun Hsu, Jih-Hsiang Lee, Chia-Chi Lin, Jin-Yuan Shih, James C.-H. Yang, Chong-Jen Yu
    European Journal of Cancer.2020; 124: 110.     CrossRef
  • Comparison detection methods for EGFR in formalin-fixed paraffin-embedded tissues of patients with NSCLC
    Xiaojie Fan, Xiaoxiao Wang, Meng Zhang, Huiyan Deng, Yueping Liu
    Pathology - Research and Practice.2020; 216(1): 152783.     CrossRef
  • Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation
    Sang Hoon Lee, Eun Young Kim, Arum Kim, Yoon Soo Chang
    Cancer Biology & Therapy.2020; 21(8): 741.     CrossRef
  • Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI
    Chi-Lu Chiang, Hsu-Ching Huang, Chia-I Shen, Yung-Hung Luo, Yuh-Min Chen, Chao-Hua Chiu
    Targeted Oncology.2020; 15(4): 503.     CrossRef
  • An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
    Shang-Gin Wu, Chi-Lu Chiang, Chien-Ying Liu, Chin-Chou Wang, Po-Lan Su, Te-Chun Hsia, Jin-Yuan Shih, Gee-Chen Chang
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment
    Jianchun Duan, JiaChen Xu, Zhijie Wang, Hua Bai, Ying Cheng, Tongtong An, Hongjun Gao, Kai Wang, Qing Zhou, Yanping Hu, Yong Song, Cuimin Ding, Feng Peng, Li Liang, Yi Hu, Cheng Huang, Caicun Zhou, Yuankai Shi, Jiefei Han, Di Wang, Yanhua Tian, Zhenlin Ya
    Journal of Thoracic Oncology.2020; 15(12): 1857.     CrossRef
  • A Highly Sensitive Next-Generation Sequencing-Based Genotyping Platform for EGFR Mutations in Plasma from Non-Small Cell Lung Cancer Patients
    Jung-Young Shin, Jeong-Oh Kim, Mi-Ran Lee, Seo Ree Kim, Kyongmin Sarah Beck, Jin Hyoung Kang
    Cancers.2020; 12(12): 3579.     CrossRef
  • Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy
    Minehiko Inomata, Kenji Azechi, Naoki Takata, Kana Hayashi, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Kazuyuki Tobe
    Diagnostics.2020; 10(12): 1006.     CrossRef
  • Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer
    Jiyun Lee, Joon Ho Shim, Woong-Yang Park, Hee Kyung Kim, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
    Cancer Research and Treatment.2019; 51(1): 408.     CrossRef
  • Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations
    Yen‐Ting Lin, Jin‐Shing Chen, Wei‐Yu Liao, Chao‐Chi Ho, Chia‐Lin Hsu, Ching‐Yao Yang, Kuan‐Yu Chen, Jih‐Hsiang Lee, Zhong‐Zhe Lin, Jin‐Yuan Shih, James Chih‐Hsin Yang, Chong‐Jen Yu
    International Journal of Cancer.2019; 144(11): 2887.     CrossRef
  • Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib
    Chih-Hsi Scott Kuo, Chi-Hsien Huang, Chien-Ying Liu, Stelios Pavlidis, Ho-Wen Ko, Fu-Tsai Chung, Tin-Yu Lin, Chih-Liang Wang, Yi-Ke Guo, Cheng-Ta Yang
    Targeted Oncology.2019; 14(4): 433.     CrossRef
  • Frecuencia de mutación T790M determinada por biopsia líquida en pacientes con cáncer pulmonar de células no pequeñas después de la progresión a inhibidores de tirosina cinasa contra EGFR en primera línea
    Jorge Arturo Alatorre-Alexander, Patricio Santillán-Doherty, María del Rosario Flores-Soto, Luis Manuel Martínez-Barrera, Jerónimo Rafael Rodríguez-Cid, Carla Paola Sánchez-Ríos
    NCT Neumología y Cirugía de Tórax.2019; 78(4): 348.     CrossRef
  • 12,775 View
  • 599 Download
  • 48 Web of Science
  • 43 Crossref
Close layer
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
Ji-Youn Han, Ki Hyeong Lee, Sang-We Kim, Young Joo Min, Eunkyung Cho, Youngjoo Lee, Soo-Hyun Lee, Hyae Young Kim, Geon Kook Lee, Byung Ho Nam, Hyesun Han, Jina Jung, Jin Soo Lee
Cancer Res Treat. 2017;49(1):10-19.   Published online May 3, 2016
DOI: https://doi.org/10.4143/crt.2016.058
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We examined the efficacy of poziotinib, a second-generation epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) in patients with lung adenocarcinoma with activating EGFR mutations, who developed acquired resistance (AR) to EGFR-TKIs.
Materials and Methods
This single-arm phase II study included EGFR-mutant lung adenocarcinoma with AR to erlotinib or gefitinib based on the Jackman criteria. Patients received poziotinib 16 mg orally once daily in a 28-day cycle. The primary endpoint was progression-free survival (PFS). Prestudy tumor biopsies and blood samples were obtained to determine resistance mechanisms.
Results
Thirty-nine patients were treated. Tumor genotyping was determined in 37 patients; 19 EGFR T790M mutations and two PIK3CAmutations were detected in the prestudy tumors, and seven T790M mutations were detected in the plasma assay. Three (8%; 95% confidence interval [CI], 2 to 21) and 17 (44%; 95% CI, 28 to 60) patients had partial response and stable disease, respectively. The median PFS and overall survival were 2.7 months (95% CI, 1.8 to 3.7) and 15.0 months (95% CI, 9.5 to not estimable), respectively. A longer PFS was observed for patients without T790M or PIK3CA mutations in tumor or plasma compared to those with these mutations (5.5 months vs. 1.8 months, p=0.003). The most frequent grade 3 adverse events were rash (59%), mucosal inflammation (26%), and stomatitis (18%). Most patients required one (n=15) or two (n=15) dose reductions.
Conclusion
Low activity of poziotinib was detected in patients with EGFR-mutant non-small cell lung cancer who developed AR to gefitinib or erlotinib, potentially because of severe-toxicityimposed dose limitation.

Citations

Citations to this article as recorded by  
  • Repeat biopsy versus initial biopsy in terms of complication risk factors and clinical outcomes for patients with non-small cell lung cancer: a comparative study of 113 CT-guided needle biopsy of lung lesions
    Yangyang Wang, Yongyuan Zhang, Nana Ren, Fangting Li, Lin Lu, Xin Zhao, Zhigang Zhou, Mengyu Gao, Meng Wang
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis
    Isabella Michelon, Maysa Vilbert, Caio Ernesto do Rego Castro, Carlos Stecca, Maria Inez Dacoregio, Manglio Rizzo, Vladmir Cláudio Cordeiro de Lima, Ludimila Cavalcante
    Journal of Personalized Medicine.2024; 14(7): 752.     CrossRef
  • 3D bioprinted vascularized lung cancer organoid models with underlying disease capable of more precise drug evaluation
    Yoo-mi Choi, Haram Lee, Minjun Ann, Minyeong Song, Jinguen Rheey, Jinah Jang
    Biofabrication.2023; 15(3): 034104.     CrossRef
  • Association of Hypokalemia Incidence and Better Treatment Response in NSCLC Patients: A Meta-Analysis and Systematic Review on Anti-EGFR Targeted Therapy Clinical Trials
    Jiawei Zhou, Jianling Bai, Yuanping Yue, Xin Chen, Theis Lange, Dongfang You, Yang Zhao
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Anlotinib plus chemotherapy for T790M‐negative EGFR‐mutant non‐sqNSCLC resistant to TKIs: A multicenter phase 1b/2 trial
    Juan Li, Yuke Tian, Min Zheng, Jun Ge, Jiliang Zhang, Dejun Kong, Mei Chen, Ping Yu
    Thoracic Cancer.2022; 13(24): 3496.     CrossRef
  • Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers
    Vidhi Malik, Vipul Kumar, Sunil C. Kaul, Renu Wadhwa, Durai Sundar
    Biomolecules.2021; 11(2): 160.     CrossRef
  • Validation of a multicellular tumor microenvironment system for modeling patient tumor biology and drug response
    Devin G. Roller, Stephen A. Hoang, Kristopher D. Rawls, Katherine A. Owen, Michael B. Simmers, Robert A. Figler, Julia D. Wulfkuhle, Emanuel F. Petricoin, Brian R. Wamhoff, Daniel Gioeli
    Scientific Reports.2021;[Epub]     CrossRef
  • Epidermal growth factor receptor inhibitor-induced diarrhea: clinical incidence, toxicological mechanism, and management
    Gabriel Tao, Pavan Kumar Chityala
    Toxicology Research.2021; 10(3): 476.     CrossRef
  • Geriatric Nutritional Risk Index as a Prognostic Factor for Mortality in Elderly Patients with Moderate to Severe Traumatic Brain Injuries
    Wei-Ti Su, Ching-Hua Tsai, Chun-Ying Huang, Sheng-En Chou, Chi Li, Shiun-Yuan Hsu, Ching-Hua Hsieh
    Risk Management and Healthcare Policy.2021; Volume 14: 2465.     CrossRef
  • Geriatric nutritional risk index in screening malnutrition among young adult and elderly trauma patients
    Yueh-Wei Liu, Ching-Hua Tsai, Sheng-En Chou, Wei-Ti Su, Chi Li, Shiun-Yuan Hsu, Ching-Hua Hsieh
    Formosan Journal of Surgery.2021; 54(5): 183.     CrossRef
  • In silico studies on p21-activated kinase 4 inhibitors: comprehensive application of 3D-QSAR analysis, molecular docking, molecular dynamics simulations, and MM-GBSA calculation
    Yinli Gao, Hanxun Wang, Jian Wang, Maosheng Cheng
    Journal of Biomolecular Structure and Dynamics.2020; 38(14): 4119.     CrossRef
  • Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC
    Iosune Baraibar, Laura Mezquita, Ignacio Gil-Bazo, David Planchard
    Critical Reviews in Oncology/Hematology.2020; 148: 102906.     CrossRef
  • Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy
    Afshin Derakhshani, Zohreh Rezaei, Hossein Safarpour, Morteza Sabri, Atefeh Mir, Mohammad Amin Sanati, Fatemeh Vahidian, Ali Gholamiyan Moghadam, Ali Aghadoukht, Khalil Hajiasgharzadeh, Behzad Baradaran
    Journal of Cellular Physiology.2020; 235(4): 3142.     CrossRef
  • Toward a More Precise Future for Oncology
    Yonina R. Murciano-Goroff, Barry S. Taylor, David M. Hyman, Alison M. Schram
    Cancer Cell.2020; 37(4): 431.     CrossRef
  • Nanocarrier centered therapeutic approaches: Recent developments with insight towards the future in the management of lung cancer
    Jigar D. Vanza, Rashmin B. Patel, Mrunali R. Patel
    Journal of Drug Delivery Science and Technology.2020; 60: 102070.     CrossRef
  • Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells
    Yongchao Zhang, Zhuo-Xun Wu, Yuqi Yang, Jing-Quan Wang, Jun Li, Zoey Sun, Qiu-Xu Teng, Charles R. Ashby, Dong-Hua Yang
    Cancers.2020; 12(11): 3249.     CrossRef
  • Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib
    Nishan Tchekmedyian, Bill Paxton, Francois Lebel, Lena Keossayan, John V. Heymach
    JTO Clinical and Research Reports.2020; 1(4): 100081.     CrossRef
  • Geriatric Nutritional Risk Index as a Screening Tool to Identify Patients with Malnutrition at a High Risk of In-Hospital Mortality among Elderly Patients with Femoral Fractures—A Retrospective Study in a Level I Trauma Center
    Wei-Ti Su, Shao-Chun Wu, Chun-Ying Huang, Sheng-En Chou, Ching-Hua Tsai, Chi Li, Shiun-Yuan Hsu, Ching-Hua Hsieh
    International Journal of Environmental Research and Public Health.2020; 17(23): 8920.     CrossRef
  • Geriatric Nutritional Risk Index as a Tool to Evaluate Impact of Malnutrition Risk on Mortality in Adult Patients with Polytrauma
    Cheng-Hsi Yeh, Shao-Chun Wu, Sheng-En Chou, Wei-Ti Su, Ching-Hua Tsai, Chi Li, Shiun-Yuan Hsu, Ching-Hua Hsieh
    International Journal of Environmental Research and Public Health.2020; 17(24): 9233.     CrossRef
  • Association between Geriatric Nutritional Risk Index and Mortality in Older Trauma Patients in the Intensive Care Unit
    Hang-Tsung Liu, Shao-Chun Wu, Ching-Hua Tsai, Chi Li, Sheng-En Chou, Wei-Ti Su, Shiun-Yuan Hsu, Ching-Hua Hsieh
    Nutrients.2020; 12(12): 3861.     CrossRef
  • Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology
    Rashmi R. Shah, Devron R. Shah
    Drug Safety.2019; 42(2): 181.     CrossRef
  • Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer
    Wei Jiang, Meiju Ji
    Seminars in Cancer Biology.2019; 59: 3.     CrossRef
  • Clinical Impact of Rare and Compound Mutations of Epidermal Growth Factor Receptor in Patients With Non–Small-Cell Lung Cancer
    Juliane Martin, Annika Lehmann, Frederick Klauschen, Michael Hummel, Dido Lenze, Christian Grohé, Antje Tessmer, Joachim Gottschalk, Berndt Schmidt, Hans-Wilhelm Pau, Christian Witt, Stefan Moegling, Robert Kromminga, Korinna Jöhrens
    Clinical Lung Cancer.2019; 20(5): 350.     CrossRef
  • Metastasiertes Lungenkarzinom – therapierbare molekulare Alterationen
    W. M. Brückl, J. H. Ficker
    Der Pneumologe.2019; 16(6): 343.     CrossRef
  • Successful Treatment of a Miliary Metastatic NSCLC Patient With Activating EGFR Exon 20 Insertion Mutation with Response to Poziotinib
    Juyin Yang, Jian Yang, Shao Ban, Xinmin Li, Xingde Chen, Jihua Yang, Jun Qian
    Journal of Thoracic Oncology.2019; 14(9): e198.     CrossRef
  • Targeting Epidermal Growth Factor Receptor in Non-Small-Cell-Lung Cancer: Current State and Future Perspective
    Shui-Ming Bao, Qing-Hui Hu, Wen-Ting Yang, Yao Wang, Yin-Ping Tong, Wen-Dai Bao
    Anti-Cancer Agents in Medicinal Chemistry.2019; 19(8): 984.     CrossRef
  • Maximum allele frequency observed in plasma: A potential indicator of liquid biopsy sensitivity
    Yong Tang, Xianling Liu, Zhu'an Ou, Zhe He, Qihang Zhu, Ye Wang, Mei Yang, Junyi Ye, Han Han‑Zhang, Guibin Qiao
    Oncology Letters.2019;[Epub]     CrossRef
  • TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
    Hibiki Udagawa, Shinichi Hasako, Akihiro Ohashi, Rumi Fujioka, Yumi Hakozaki, Mikiko Shibuya, Naomi Abe, Toshiharu Komori, Tomonori Haruma, Miki Terasaka, Ryoto Fujita, Akihiro Hashimoto, Kaoru Funabashi, Hiroyuki Yasuda, Kazutaka Miyadera, Koichi Goto, D
    Molecular Cancer Research.2019; 17(11): 2233.     CrossRef
  • Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor
    Chengying Xie, Xiaozhe Wan, Haitian Quan, Mingyue Zheng, Li Fu, Yun Li, Liguang Lou
    Cancer Science.2018; 109(4): 1207.     CrossRef
  • Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer
    Jacqulyne P. Robichaux, Yasir Y. Elamin, Zhi Tan, Brett W. Carter, Shuxing Zhang, Shengwu Liu, Shuai Li, Ting Chen, Alissa Poteete, Adriana Estrada-Bernal, Anh T. Le, Anna Truini, Monique B. Nilsson, Huiying Sun, Emily Roarty, Sarah B. Goldberg, Julie R.
    Nature Medicine.2018; 24(5): 638.     CrossRef
  • Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma
    In-Jae Oh, Jae Young Hur, Cheol-Kyu Park, Young-Chul Kim, Seung Joon Kim, Min Ki Lee, Hee Joung Kim, Kye Young Lee, Jae Cheol Lee, Chang-Min Choi
    Clinical Lung Cancer.2018; 19(5): e775.     CrossRef
  • Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors
    Yanmei Peng, Qiang Li, Jingyi Zhang, Wen Shen, Xu Zhang, Chenyao Sun, Huijuan Cui
    BioScience Trends.2018; 12(6): 537.     CrossRef
  • EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
    Susan E. Jorge, Antonio R. Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu S. Kobayashi, Daniel B. Costa
    Clinical Cancer Research.2018; 24(24): 6548.     CrossRef
  • EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs
    Zhiyong Liang, Ying Cheng, Yuan Chen, Yanping Hu, Wei-Ping Liu, You Lu, Jie Wang, Ye Wang, Gang Wu, Jian-Ming Ying, He-Long Zhang, Xu-Chao Zhang, Yi-Long Wu
    Cancer Letters.2017; 403: 186.     CrossRef
  • Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer
    Xuefei Li, Caicun Zhou
    Oncotarget.2017; 8(59): 100801.     CrossRef
  • 14,593 View
  • 563 Download
  • 37 Web of Science
  • 35 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP